Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab tirumotecan + almonertinib first-line in EGFR-mutant NSCLC with high PD-L1
ChiCTR2600128212Phase 2Not yet recruiting
- Sponsor
- Affiliated Hospital of Hebei University
- Start
- Jul 2026
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan and almonertinib in non-small cell lung cancer (NSCLC), sponsored by Affiliated Hospital of Hebei University. Primary endpoint: Objective response rate (ORR). Planned start Jul 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecanalmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600128212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128212.